Načítá se...
Current and future standards in treatment of myasthenia gravis
Myasthenia gravis (MG) is a prototypic antibody-mediated neurological autoimmune disorder. Herein we characterize modern treatment algorithms that are adapted to disease severity, and introduce the current principles of escalating strategies for MG treatment. In non-thymoma patients younger than abo...
Uloženo v:
| Vydáno v: | Neurotherapeutics |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer New York
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4514693/ https://ncbi.nlm.nih.gov/pubmed/19019304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nurt.2008.08.011 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|